Table 2.
Baseline serum leptin levels and number of physical disorders by 12-week and 12-month remission status
| Exposure variable | Up to 12-week treatment (n = 1,086) | Up to 12-month treatment (n = 884) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
||||||||
| Non-remission (n = 596) | Remission (n = 490) | Statistical coefficientsa | pvalue | Non-remission (n = 259) | Remission (n = 625) | Statistical coefficientsa | pvalue | ||
| Leptin (ng/ml) | |||||||||
| Median (IQR) | 6.1 (6.6) | 5.3 (5.7) | U = 124,592.0 | < 0.001 | 6.0 (6.0) | 5.6 (6.1) | U = 77,199.0 | 0.317 | |
| Low:High, n (%) | 265 (44.5):331 (55.5) | 277 (56.5):213 (43.5) | χ2 = 15.664 | 0.001 | 131 (50.6):128 (49.4) | 315 (50.4):310 (49.6) | χ2 = 0.002 | 0.961 | |
| Number of physical disorders | |||||||||
| Median (IQR) | 1.0 (1.0) | 2.0 (1.0) | U = 138,405.5 | 0.128 | 1.0 (1.0) | 2.0 (1.0) | U = 79,760.0 | 0.726 | |
| < 2: ≥ 2, n (%) | 317 (53.2):279 (46.8) | 233 (47.6):257 (52.4) | χ2 = 3.418 | 0.064 | 133 (51.4):126 (48.6) | 316 (50.6) | χ2 = 0.268 | 0.605 | |
IQR, interquartile range.
aMann−Whitney Utest or χ2 test, as appropriate.